BCBS North Carolina

Does BCBS North Carolina cover Ozempic?

Quick answer · Type 2 Diabetes

BCBS North Carolina covers Ozempic for type 2 diabetes with prior authorization on Employer / Commercial Insurance.

  • Employer / Commercial Insurance: Covered with requirements. Diagnosis documented with a code

Last verified June 2, 2026. Policy effective May 1, 2026. Source: glp1-agonists-nc-standard.pdf. How we verify this data →

Check your card for your exact plan →

Ozempic for Type 2 Diabetes

What BCBS North Carolina requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • Diagnosis documented with a code

Qualification pathways

You can qualify through any one of these.

New patient - prior therapy requirement

All of:

  • Diagnosis of type 2 diabetes mellitus (medical record documentation required)
  • Requested product will not be taken concomitantly with a DPP-4 containing agent
  • Requested product will not be taken concomitantly with another GLP-1 agonist

Plus any one of:

  • Patient has tried and had an inadequate response, intolerance, or hypersensitivity to an agent containing metformin, sulfonylurea, or insulin
  • Patient has an FDA labeled contraindication to metformin
  • Patient has a diagnosis of, or is at high risk for, atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, and/or MASH

Continuity of care - currently on therapy

All of:

  • Diagnosis of type 2 diabetes mellitus (medical record documentation required)
  • Prescriber states patient is currently being treated with the requested agent within the past 90 days and is at risk if therapy is changed
  • Requested product will not be taken concomitantly with a DPP-4 containing agent
  • Requested product will not be taken concomitantly with another GLP-1 agonist

Documentation to bring

  • Medical record documentation of type 2 diabetes mellitus diagnosis
  • Documentation of prior trial with inadequate response, intolerance, or hypersensitivity to metformin, sulfonylurea, or insulin OR FDA labeled contraindication to metformin OR diagnosis of/high risk for ASCVD, heart failure, CKD, or MASH (OR attestation that patient is currently on this agent within the past 90 days and at risk if changed)
  • Attestation that requested product will not be taken concomitantly with a DPP-4 containing agent
  • Attestation that requested product will not be taken concomitantly with another GLP-1 agonist

Quantity limits

  • 0.25mg/dose (2mg/3mL pen), 0.5mg/dose (2mg/3mL pen) — 3 mL (1 pen)
  • 1mg/dose (4mg/3mL pen) — 3 mL (1 pen)
  • 2mg/dose (8mg/3mL pen) — 3 mL (1 pen)

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months

Not covered when

  • Concomitant use with DPP-4 containing agent
  • Concomitant use with another GLP-1 agonist

Policy note: Ozempic injection is approved for T2DM in adults only per FDA labeling cited in this policy. Ozempic tablets (new to market) were added to this policy in May 2026. The criteria for Ozempic injection and Ozempic tablets are the same in this document.

Policy effective May 1, 2026 · verified June 2, 2026 · source: glp1-agonists-nc-standard.pdf

Ozempic for Heart Disease Risk Reduction

What BCBS North Carolina requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • Diagnosis documented with a code

Qualification pathways

You can qualify through any one of these.

CV risk reduction - new patient (requires T2DM + prior therapy or comorbidity)

All of:

  • Diagnosis of type 2 diabetes mellitus (medical record documentation required)
  • Established cardiovascular disease OR high risk for cardiovascular events (per FDA labeling for Ozempic/Rybelsus)
  • Requested product will not be taken concomitantly with a DPP-4 containing agent
  • Requested product will not be taken concomitantly with another GLP-1 agonist

Plus any one of:

  • Patient has tried and had an inadequate response, intolerance, or hypersensitivity to an agent containing metformin, sulfonylurea, or insulin
  • Patient has an FDA labeled contraindication to metformin
  • Patient has a diagnosis of, or is at high risk for, atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, and/or MASH

CV risk reduction - continuity of care

All of:

  • Diagnosis of type 2 diabetes mellitus (medical record documentation required)
  • Prescriber states patient is currently being treated with the requested agent within the past 90 days and is at risk if therapy is changed
  • Requested product will not be taken concomitantly with a DPP-4 containing agent
  • Requested product will not be taken concomitantly with another GLP-1 agonist

Documentation to bring

  • Medical record documentation of type 2 diabetes mellitus diagnosis
  • Documentation of established cardiovascular disease or high cardiovascular risk
  • Documentation of prior trial with inadequate response, intolerance, or hypersensitivity to metformin, sulfonylurea, or insulin OR FDA labeled contraindication to metformin OR diagnosis of/high risk for ASCVD, heart failure, CKD, or MASH (OR attestation that patient is currently on this agent within the past 90 days and at risk if changed)
  • Attestation that requested product will not be taken concomitantly with a DPP-4 containing agent
  • Attestation that requested product will not be taken concomitantly with another GLP-1 agonist

Quantity limits

  • 0.25mg/dose (2mg/3mL pen), 0.5mg/dose (2mg/3mL pen) — 3 mL (1 pen)
  • 1mg/dose (4mg/3mL pen) — 3 mL (1 pen)
  • 2mg/dose (8mg/3mL pen) — 3 mL (1 pen)

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months

Not covered when

  • Concomitant use with DPP-4 containing agent
  • Concomitant use with another GLP-1 agonist

Policy note: This policy does not have separate approval criteria for the CV risk reduction indication vs. the diabetes indication — all approvals require T2DM diagnosis plus prior therapy or comorbidity. The CV risk reduction indication is recognized per FDA labeling cited in the document. T2DM is REQUIRED (does not exclude diabetes). Rybelsus also shares the CV risk reduction indication per this policy (Nov 2025 update).

Policy effective May 1, 2026 · verified June 2, 2026 · source: glp1-agonists-nc-standard.pdf

Ozempic for Kidney Disease (CKD)

What BCBS North Carolina requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • Diagnosis documented with a code

Qualification pathways

You can qualify through any one of these.

CKD indication - new patient (requires T2DM + prior therapy or comorbidity)

All of:

  • Diagnosis of type 2 diabetes mellitus (medical record documentation required)
  • Chronic kidney disease diagnosis
  • Requested product will not be taken concomitantly with a DPP-4 containing agent
  • Requested product will not be taken concomitantly with another GLP-1 agonist

Plus any one of:

  • Patient has tried and had an inadequate response, intolerance, or hypersensitivity to an agent containing metformin, sulfonylurea, or insulin
  • Patient has an FDA labeled contraindication to metformin
  • Patient has a diagnosis of, or is at high risk for, atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, and/or MASH

CKD indication - continuity of care

All of:

  • Diagnosis of type 2 diabetes mellitus (medical record documentation required)
  • Prescriber states patient is currently being treated with the requested agent within the past 90 days and is at risk if therapy is changed
  • Requested product will not be taken concomitantly with a DPP-4 containing agent
  • Requested product will not be taken concomitantly with another GLP-1 agonist

Documentation to bring

  • Medical record documentation of type 2 diabetes mellitus diagnosis
  • Documentation of chronic kidney disease diagnosis
  • Documentation of prior trial with inadequate response, intolerance, or hypersensitivity to metformin, sulfonylurea, or insulin OR FDA labeled contraindication to metformin OR diagnosis of/high risk for ASCVD, heart failure, CKD, or MASH (OR attestation that patient is currently on this agent within the past 90 days and at risk if changed)
  • Attestation that requested product will not be taken concomitantly with a DPP-4 containing agent
  • Attestation that requested product will not be taken concomitantly with another GLP-1 agonist

Quantity limits

  • 0.25mg/dose (2mg/3mL pen), 0.5mg/dose (2mg/3mL pen) — 3 mL (1 pen)
  • 1mg/dose (4mg/3mL pen) — 3 mL (1 pen)
  • 2mg/dose (8mg/3mL pen) — 3 mL (1 pen)

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months

Not covered when

  • Concomitant use with DPP-4 containing agent
  • Concomitant use with another GLP-1 agonist

Policy note: CKD indication for Ozempic injection added per Feb 2025 policy update. The policy does not specify separate or different PA criteria for the CKD indication beyond T2DM diagnosis requirement and step therapy; CKD diagnosis itself can satisfy the comorbidity exception to metformin step therapy. T2DM is required concurrently per FDA labeling cited.

Policy effective May 1, 2026 · verified June 2, 2026 · source: glp1-agonists-nc-standard.pdf

Why Ozempic requests get denied by BCBS North Carolina

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Ozempic and Wegovy are the same molecule with different approved uses; a request for Ozempic under a diagnosis that matches Wegovy is routinely denied.
  2. Diagnosis code missing or wrong on the request.

Frequently asked questions

Does BCBS North Carolina cover Ozempic?
BCBS North Carolina covers Ozempic for type 2 diabetes with prior authorization on Employer / Commercial Insurance.
How long does a Ozempic approval last with BCBS North Carolina?
Initial approvals last 12 months, and renewals are granted in 12-month periods.
How current is this information?
This page reflects BCBS North Carolina's written policy as of May 1, 2026, last verified against the source document on June 2, 2026.

Other medications under BCBS North Carolina

Ozempic coverage under other plans

All insurance plans · All medications

This page summarizes BCBS North Carolina's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.